Results 31 to 40 of about 118,712 (218)

Alkaloids from the Sponge Stylissa carteri Present Prospective Scaffolds for the Inhibition of Human Immunodeficiency Virus 1 (HIV-1). [PDF]

, 2016
The sponge Stylissa carteri is known to produce a number of secondary metabolites displaying anti-fouling, anti-inflammatory, and anti-cancer activity. However, the anti-viral potential of metabolites produced by S.
Bader, Theresa Maria, Brack-Werner, Ruth, Gerwick, William H, Helfer, Markus, Kremb, Stephan, O'Rourke, Aubrie, Schmitt-Kopplin, Philippe, Voolstra, Christian R   +7 more
core   +2 more sources

Inhibitory effect of aqueous dandelion extract on HIV-1 replication and reverse transcriptase activity

BMC Complementary and Alternative Medicine, 2011
Background Acquired immunodeficiency syndrome (AIDS), which is caused by the human immunodeficiency virus (HIV), is an immunosuppressive disease that results in life-threatening opportunistic infections.
Han Huamin, He Wen, Wang Wei, Gao Bin
doaj   +1 more source

Adaptive HIV-1 evolutionary trajectories are constrained by protein stability [PDF]

, 2017
Despite the use of combination antiretroviral drugs for the treatment of HIV-1 infection, the emergence of drug resistance remains a problem. Resistance may be conferred either by a single mutation or a concerted set of mutations.
Kandathil, Shaun M., Lovell, Simon C., Olabode, Abayomi S., Robertson, David L.   +3 more
core   +2 more sources

Human immunodeficiency virus treatment-induced adipose tissue pathology and lipoatrophy: Prevalence and metabolic consequences [PDF]

, 2010
Lipoatrophy and metabolic complications of treatment of human immunodeficiency virus (HIV) infection may share common associations with adipose tissue pathology and inflammation.
Hammond, E.L., McKinnon, E., Nolan, D.
core   +2 more sources

A Review of Electroanalytical Techniques for Determination of Anti-HIV Drugs

International Journal of Electrochemistry, 2011
Until now after the human immunodeficiency virus (HIV) was discovered as the then tentative aetiological agent of acquired immune deficiency syndrome (AIDS), exactly 25 anti-HIV compounds have been formally approved for clinical use in the treatment of ...
Burçin Bozal, Bengi Uslu, Sibel A. Özkan   +2 more
doaj   +1 more source

Synthesis of Quinolin-2-one Alkaloid Derivatives and Their Inhibitory Activities against HIV-1 Reverse Transcriptase

Molecules, 2011
Based on an established common pharmacophore of HIV-1 non-nucleoside reverse transcriptase inhibitors (NNTTIs), a series of quinolin-2-one derivatives were synthesized and assayed for their in vitro activities against HIV-1 reverse transcriptase (RT) for
Pi Cheng, Qiong Gu, Wei Liu, Jian-Feng Zou, Yang-Yong Ou, Zhong-Yong Luo, Jian-Guo Zeng   +6 more
doaj   +1 more source

Drug resistance and viral tropism in HIV-1 subtype C-infected patients in KwaZulu-Natal, South Africa: implications for future treatment options [PDF]

, 2011
Article approval pendingDrug resistance poses a significant challenge for the successful application of highly active antiretroviral therapy (HAART) globally. Furthermore, emergence of HIV-1 isolates that preferentially use CXCR4 as a coreceptor for cell
Ashika Singh, Bjorndal, Brenner, Briggs, Briz, Cann, Cecilia, Cilliers, Coakley, Coetzer, Connor, Cozzi-Lepri, Daniel R. Kuritzkes, Elizabeth D. Anton, Fouchier, Fouchier, Furtado, Henry Sunpath, Hosseinipour, Hunt, Irlbeck, Jacqueline D. Reeves, Johnston, Kantor, Keshni Hiramen, Kuiken, Loemba, Low, Marconi, Nagavelli Padayachi, Ndungu, Novitsky, Reeves, Richard Murphy, Rizzuto, Scarlatti, Singh, Tamura, Taryn N. Green, Taylor, Thumbi Ndung'u, Tobin, Trinh, Tscherning, Wallis, Westby, Whitcomb, Wu, Yolanda Lie   +48 more
core   +2 more sources

The role of drug resistance in poor viral suppression in rural South Africa: findings from a population-based study. [PDF]

, 2020
BACKGROUND:Understanding factors driving virological failure, including the contribution of HIV drug resistance mutations (DRM), is critical to ensuring HIV treatment remains effective.
Barnhart, Scott, Gilmore, Hailey J, Grignon, Jessica S, Hunt, Gillian, Liegler, Teri, Lippman, Sheri A, Mooney, Alyssa C, Prach, Lisa M, Puren, Adrian, Truong, Hong-Ha M   +9 more
core  

Nevirapine versus Efavirenz for patients co-infected with HIV and Tuberculosis: A Randomised Non-Inferiority Trial [PDF]

, 2013
BACKGROUND: In countries with a high incidence of HIV and tuberculosis co-infection, nevirapine and efavirenz are widely used as antiretroviral therapy but both interact with antituberculosis drugs. We aimed to compare efficacy and safety of a nevirapine-
Agnès Sobry, Alexandra Calmy, Anne-Marie Taburet, Avihingsanon, Blackwelder, Boulle, Carlota Silva, Chen, Christine Rouzioux, Christophe Michon, Cohen, Cohen, Davies, Dejesus, Dieterich, Elisabeth Baudin, Elizabete Nunes, Flandre, Ford, Gengiah, Gulick, Ilesh Jani, Kwara, Laura Ciaffi, Maartens, Manosuthi, Manosuthi, Maryline Bonnet, Matteelli, Mbuagbaw, Meintjes, Nilesh Bhatt, Rui Bastos, Scourfield, Shipton, Soriano, Swaminathan, Tang, Telenti, van Leth   +39 more
core   +3 more sources

A comparison of the ability of rilpivirine (TMC278) and selected analogues to inhibit clinically relevant HIV-1 reverse transcriptase mutants

Retrovirology, 2012
Background The recently approved anti-AIDS drug rilpivirine (TMC278, Edurant) is a nonnucleoside inhibitor (NNRTI) that binds to reverse transcriptase (RT) and allosterically blocks the chemical step of DNA synthesis.
Johnson Barry C, Pauly Gary T, Rai Ganesha, Patel Disha, Bauman Joseph D, Baker Heather L, Das Kalyan, Schneider Joel P, Maloney David J, Arnold Eddy, Thomas Craig J, Hughes Stephen H   +11 more
doaj   +1 more source